Product Images Aripiprazole

ARIPiprazole is a medication with an NDC code of 70518-2580-00. It comes in tablet form with a quantity of 30 and a strength of 10 mg. The source NDC is 13668-0218-05, and the manufacturer is Torrent Pharma Inc, located in Basking Ridge, NJ 07920. The medication should be stored between 15-30°C (59-86°F) and out of the reach of children. The expiration date and lot number are not available. This medication requires a prescription and was repackaged by RemedyRepack Inc. in Indiana, PA 15701. For proper usage directions, refer to the package insert.*

This is a figure showing the effects of different drugs on the pharmacokinetics of aripiprazole. The drugs include inhibitors of CYP3A4 and CYP2D6 enzymes, an inducer of CYP3M4 enzyme, gastric acid blockers, valproate, lithium, and lorazepam. The fold change and 90% confidence interval of aripiprazole levels are shown relative to a reference without any interacting drug.*

Figure 2 shows the effects of other drugs on the pharmacokinetics of dehydro-aripiprazole. The fold change in PK of dehydro-aripiprazole and its 90% confidence interval are presented for different drugs including cypaps, aundne, Gasric dBeckars, and oner. The change is presented relative to the reference (without interfering drugs).*

This is a useful table presented as Figure 3 which demonstrates the impact of Aripiprazole medication on the pharmacokinetics of other drugs. The table shows the fold change and 50% confidence intervals of Aripiprazole interaction with various medications (deropmetoptan, cvpace, artann, Roartain, omeprazole, UoTiAd, lamotigine, valproate, lithium, lorazepam, venidaine, Odesmyhenataing and escitiopram). The changes in reference to drugs without interacting medications are recorded on a scale of 5 to 30.*

The image shows the effects of intrinsic factors on aripiprazole pharmacokinetics. It includes the fold change and 90% confidence interval for special populations based on gender, age, hepatic and renal impairment. The results depict the impact of intrinsic factors on aripiprazole's AUC, Cmax, and a few other parameters.*

The text describes the effects of intrinsic factors on the pharmacokinetics of dehydro-aripiprazole, including CYP2D6 metabolizer status, gender, age, and hepatic and renal impairment. It presents the fold changes and confidence intervals in AUC and Cmax for different comparisons of these factors. The figure shows a graph with relative changes to the reference values.*

The image shows a graph of the cumulative proportion of patients with relapse in a schizophrenia study comparing Aripiprazole and Placebo. There is also a table showing the number of subjects at risk for each arm of the study. The x-axis of the graph shows the days since randomization.*

This is a Kaplan-Meier estimation graph displaying the cumulative proportion of patients with relapse in a bipolar study. The graph compares the effects of Aripiprazole (ARPPRAZOLE) against a placebo in reducing the incidence of relapse. The number of subjects at risk is shown on the left side of the graph, and the days from randomization are shown at the bottom.*

The figure shows the Kaplan-Meier estimation of the cumulative proportion of patients who relapsed to any mood event in Bipolar Study 8. The proportion of patients with relapse is plotted against the days from randomization. The text also mentions the medication names ABILIFY and LACE and their corresponding numbers.*

This appears to be a figure caption showing the least square means of change in YGTSS TTS (total tic score) by week for Tourette's Disorder Study 1. The figure is not available for review, so no further information can be provided.*